Lemzoparlimab is a whole-human monoclonal antibody against CD47 and is used as a single agent to treat relapsed or refractory acute myeloid leukemia (NCT04202003) and MDS in phase I/II (NCT04895410). Here, CD47 is linked to myelodysplastic syndrome.